KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial.

Junqiang Chen, Xiao Chang, Wenyang Liu, Xiaomin Wang, Xiaolin Ge, Ke Liu, Lei Deng, Miaomiao Hu, Jianchao Lu, Wei Wang, Haiwen Zhou, Shuai Qie, Jihong Zhang, Weiming Han, Wenqing Wang, Zongmei Zhou, Xin Wang, Jun Liang, Nan Bi, Tao Zhang, Jianyang Wang, Yirui Zhai, Lan Wang, Yu Lin, Yidian Zhao, Qingsong Pang, Xinchen Sun, Yonggang Shi, Kaixian Zhang, Ling Li, Qifeng Wang, Minghe Li, Hongyun Shi, Zhilong Yu, Wei Deng, Chun Han, Junjie Wang, Wanqing Chen, Wencheng Zhang, Zefen Xiao, Jing-Jin-Ji Esophageal, Esophagogastric Cancer Radiotherapy Oncology Group 3JECROG

Radiother Oncol 218 111334

PMID41412437
PMCID-
DOI10.1016/j.radonc.2025.111334
发表日期2025-12-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: This study reports the long-term outcomes of simultaneous integrated boost radiotherapy (SIB-RT) combined with oral S-1 chemotherapy (CRTCT) in inoperable patients aged ≥ 70 years with inoperable esophageal squamous cell carcinoma (ESCC). METHODS: In this multicenter, phase III randomized trial, patients with inoperable, locally advanced stage II-IV ESCC were randomized to receive either CRTCT or RT alone. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), restricted mean survival time (RMST), and patterns of failure. RESULTS: After a median follow-up of 75 months, patients in the CRTCT group had longer OS than those in the RT group (hazard ratio (HR), 0.74; 95 % confidence interval (CI), 0.57-0.95; P = 0.02), with better 5-year OS rates (34.1 % vs. 23.6 %,P = 0.02), PFS (31.1 % vs. 20.9 %,P = 0.02), and RMST (33.0 vs. 27.0 months,P = 0.02). CRTCT's effect on OS stabilized over 5 years. Locoregional failure was lower in the CRTCT group (HR, 0.64; 95 % CI, 0.45-0.92; P = 0.02), with similar distant and mixed failure risks. CONCLUSIONS: SIB-RT combined with oral S-1 chemotherapy significantly improved long-term survival and therefore might be considered a standard of care for elderly patients with inoperable ESCC. TRIAL REGISTRATION Clinical Trials.gov Identifier: NCT0297969.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。